Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries (NCT03192696) | Clinical Trial Compass
CompletedNot Applicable
Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries
United States127 participantsStarted 2017-10-19
Plain-language summary
A prospective, non-randomized, international, multi-center study to evaluate the safety and effectiveness of the Pantheris OCT-Imaging System to perform atherectomy in In-Stent Restenotic (ISR) lesions in lower extremity arteries.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject is \>18 years old;
* Subject is willing and able to give informed consent;
* Subject has Rutherford Classification of I-V;
* Subject presenting with a single Class I, II or III ISR lesion as per Tosaka's Classification criteria in the lower leg extremities;
* Target lesion must be \>70% stenosed and within a stented segment by angiographic visual estimation;
* Reference vessel lumen acceptable for treatment with Pantheris catheter size as per visual angiographic estimation;
* Target lesions must be within the stented segment and no more than 3 cm past the proximal or distal portions of the stent;
* Target lesion is ≤30 cm in length;
* Intraluminal crossing of totally occluded lesions prior to atherectomy;
* At least one patent tibial run-off vessel at baseline; and
* Subject is capable of meeting requirements and be present at the follow-up clinic visits at 30 days, 6 months and 12 months.
Exclusion Criteria:
* Subject is pregnant or breast feeding;
* Rutherford Class 0 or VI;
* Severe calcification of the target lesion;
* Acute ischemia and/or acute thrombosis of the target lesion segment;
* Target lesion with a covered stent;
* Target lesion in the iliac artery;
* Target lesion stenosis \<70%;
* Target lesion \>30 cm in length;
* Subjects with totally occluded stented segments that are not successfully crossed intraluminally prior to atherectomy treatment;
* Grade 4 or 5 stent fracture affecting target stent, or where evidence of stent protr…
What they're measuring
1
Freedom from a composite of major adverse events (MAEs) through 30-day follow-up (safety)
Timeframe: Day 0 through 30 days post treatment procedure
2
Technical success of Pantheris catheter treatment (efficacy) device